Neelanjana Ray, Ph.D.
Affiliations: | 2004 | Princeton University, Princeton, NJ |
Area:
virology, circuit tracers, pathogenesisGoogle:
"Neelanjana Ray"Mean distance: 17.54 (cluster 32) | S | N | B | C | P |
Parents
Sign in to add mentor| Lynn W. Enquist | grad student | 2004 | Princeton | |
| (Host transcriptional response to alphaherpesvirus infections: Implications of COX-2 induction on virus growth.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Dicker I, Zhang S, Ray N, et al. (2019) Resistance profile of the HIV-1 maturation inhibitor GSK3532795 in vitro and in a clinical study. Plos One. 14: e0224076 |
| Gay CL, Bosch RJ, Ritz J, et al. (2017) Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy. The Journal of Infectious Diseases |
| Hwang C, Schürmann D, Sobotha C, et al. (2017) Antiviral Activity, Safety, and Exposure-Response relationships of GSK3532795, a Second-Generation HIV-1 Maturation Inhibitor, administered as Monotherapy or in Combination with Atazanavir±Ritonavir in a Phase 2a Randomized, Dose-Ranging, Controlled Trial (AI468002). Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America |
| Ray N, Li T, Lin Z, et al. (2017) The second-generation maturation inhibitor GSK3532795 maintains potent activity toward HIV protease inhibitor-resistant clinical isolates. Journal of Acquired Immune Deficiency Syndromes (1999) |
| Gupta SK, McComsey GA, Lombaard J, et al. (2016) Efficacy, safety, bone and metabolic effects of HIV nucleoside reverse transcriptase inhibitor BMS-986001 (AI467003): a phase 2b randomised, controlled, partly blinded trial. The Lancet. Hiv. 3: e13-22 |
| Zhou N, Nowicka-Sans B, McAuliffe B, et al. (2014) Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068. The Journal of Antimicrobial Chemotherapy. 69: 573-81 |
| Li Z, Zhou N, Sun Y, et al. (2013) Activity of the HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068, against CD4-independent viruses and HIV-1 envelopes resistant to other entry inhibitors. Antimicrobial Agents and Chemotherapy. 57: 4172-80 |
| Ray N, Hwang C, Healy MD, et al. (2013) Prediction of virological response and assessment of resistance emergence to the HIV-1 attachment inhibitor BMS-626529 during 8-day monotherapy with its prodrug BMS-663068. Journal of Acquired Immune Deficiency Syndromes (1999). 64: 7-15 |
| Nettles RE, Schürmann D, Zhu L, et al. (2012) Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects. The Journal of Infectious Diseases. 206: 1002-11 |
| Nowicka-Sans B, Gong YF, McAuliffe B, et al. (2012) In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068. Antimicrobial Agents and Chemotherapy. 56: 3498-507 |